Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via P. Maroncelli 40, Meldola, FC, 47014, Italy.
Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, Meldola, FC, 47014, Italy.
Support Care Cancer. 2021 May;29(5):2735-2742. doi: 10.1007/s00520-020-05718-0. Epub 2020 Sep 28.
Cost evaluation is becoming mandatory to support healthcare sustainability and optimize the decision-making process. This topic is a challenge, especially for complex and rapidly evolving treatment modalities such as radiotherapy (RT). The aim of the present study was to investigate the cost of RT in the last month of life of patients in an Italian cancer center.
This was a retrospective study on a cancer population (N= 160) who underwent RT or only an RT planning simulation in an end of life (EOL) setting. The cost of RT procedures performed on patients was collected according to treatment status, care setting, and RT technique used. Costs were valued according to the sum of reimbursements relating to all procedures performed and assessed from the perspective of the National Health System.
The total cost of RT in the last month of life was €244,774, with an average cost per patient of €1530. Around 7.7% and 30.3% of the total cost was associated with patients who never started RT or who discontinued RT, respectively, while the remaining 62.0% referred to patients who completed treatment. Costs associated with outpatient and inpatient settings represented 54.3% and 38.6% of the total cost, respectively. The higher average cost per patient for the never-started and discontinued groups was correlated with patients who had a poor ECOG Performance Status.
Improved prognostic accuracy and a better integration between radiotherapy and palliative care units could be a key to a better use of resources and to a reduction in the cost of EOL RT.
为了支持医疗保健的可持续性并优化决策过程,成本评估变得越来越重要。对于放射治疗(RT)等复杂且快速发展的治疗方式,这是一个挑战。本研究的目的是调查意大利癌症中心临终患者 RT 的成本。
这是一项针对癌症患者(N=160)的回顾性研究,这些患者在临终(EOL)环境下接受了 RT 或仅接受了 RT 计划模拟。根据治疗状况、护理环境和使用的 RT 技术,收集了对患者进行的 RT 程序的成本。根据与所有执行的程序相关的报销总和来评估成本,并从国家卫生系统的角度进行评估。
临终前一个月的 RT 总费用为 244774 欧元,每位患者的平均费用为 1530 欧元。从未开始 RT 或停止 RT 的患者分别占总费用的 7.7%和 30.3%,而其余 62.0%的患者则完成了治疗。门诊和住院环境的成本分别占总费用的 54.3%和 38.6%。从未开始和停止 RT 的患者的平均每位患者的费用较高,与 ECOG 表现状态较差的患者相关。
提高预后准确性和更好地整合放射治疗和姑息治疗单位可能是更好地利用资源和降低 EOL RT 成本的关键。